ATE554105T1 - Veränderte antikörper - Google Patents
Veränderte antikörperInfo
- Publication number
- ATE554105T1 ATE554105T1 AT07804411T AT07804411T ATE554105T1 AT E554105 T1 ATE554105 T1 AT E554105T1 AT 07804411 T AT07804411 T AT 07804411T AT 07804411 T AT07804411 T AT 07804411T AT E554105 T1 ATE554105 T1 AT E554105T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- altered antibodies
- relates
- engineering
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0619291.8A GB0619291D0 (en) | 2006-09-29 | 2006-09-29 | Altered antibodies |
| PCT/GB2007/003706 WO2008038024A1 (en) | 2006-09-29 | 2007-09-28 | Altered antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE554105T1 true ATE554105T1 (de) | 2012-05-15 |
Family
ID=37434965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07804411T ATE554105T1 (de) | 2006-09-29 | 2007-09-28 | Veränderte antikörper |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8507654B2 (de) |
| EP (1) | EP2074143B1 (de) |
| AT (1) | ATE554105T1 (de) |
| DK (1) | DK2074143T3 (de) |
| ES (1) | ES2384807T3 (de) |
| GB (1) | GB0619291D0 (de) |
| WO (1) | WO2008038024A1 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| EP2308897A1 (de) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011117653A1 (en) | 2010-03-25 | 2011-09-29 | Ucb Pharma S.A. | Disulfide stabilized dvd-lg molecules |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| BR112014006175B1 (pt) | 2011-09-16 | 2020-02-11 | Ucb Pharma S.A. | Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile |
| EP3539982B1 (de) * | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür |
| GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| WO2014078623A2 (en) * | 2012-11-15 | 2014-05-22 | Brandeis University | Tethering cysteine residues using cyclic disulfides |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| KR20160097336A (ko) | 2013-12-12 | 2016-08-17 | 스템센트알엑스 인코포레이티드 | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| EP3107576A4 (de) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| KR20170138570A (ko) | 2015-04-30 | 2017-12-15 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질 |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| JP6851322B2 (ja) | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| SG10202010735PA (en) | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
| US10711261B2 (en) | 2015-08-18 | 2020-07-14 | Brandeis University | Tethering cysteine residues using cyclic disulfides |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| WO2017120534A1 (en) | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
| GB201602414D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Biological materials and uses thereof |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3504244A4 (de) | 2016-08-26 | 2020-08-19 | Agency for Science, Technology and Research | Makrophagenstimulierender proteinrezeptor (oder ron - recepteur d' origine nantais)-antikörper und verwendungen davon |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| EP3824906A1 (de) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antikörperformulierungen |
| US20200165347A1 (en) | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| AU2019235634A1 (en) | 2018-03-13 | 2020-10-22 | Zymeworks Bc Inc. | Anti-HER2 biparatopic antibody-drug conjugates and methods of use |
| AU2019289176B2 (en) | 2018-06-18 | 2026-02-19 | Adelaide university | Gremlin-1 antagonist for the prevention and treatment of cancer |
| GB201811368D0 (en) | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| WO2020197502A1 (en) | 2019-03-26 | 2020-10-01 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-il-13r antibody or binding fragment thereof |
| US12076400B2 (en) | 2019-12-06 | 2024-09-03 | Zymeworks Bc Inc. | Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| BR112023008265A2 (pt) | 2020-12-07 | 2024-02-06 | UCB Biopharma SRL | Anticorpos contra interleucina-22 |
| WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
| WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| AR125732A1 (es) | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | Anticuerpos anti-trem1 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| JP2024534717A (ja) | 2021-09-27 | 2024-09-24 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 中等症から重症のアトピー性皮膚炎の処置のための方法 |
| WO2023075702A1 (en) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
| TW202337905A (zh) | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體之糖基化形式 |
| KR20250075749A (ko) | 2022-08-26 | 2025-05-28 | 아슬란 파마슈티컬스 피티이 엘티디 | 항-il13r 항체의 고농도 제형 |
| CN120077070A (zh) | 2022-09-06 | 2025-05-30 | 亚狮康私人有限公司 | 皮炎患者的睡眠缺失或睡眠障碍的治疗 |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| TW202613165A (zh) | 2024-05-17 | 2026-04-01 | 比利時商Ｕｃｂ生物製藥公司 | 具有il-11和il-17結合特異性的多特異性抗體 |
| WO2025238135A2 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Antibody with binding specificity for il-11 |
| WO2026027660A1 (en) | 2024-08-02 | 2026-02-05 | UCB Biopharma SRL | Formulations of anti-gremlin-1 antibodies |
| WO2026055183A1 (en) | 2024-09-03 | 2026-03-12 | Vir Biotechnology, Inc | Antiviral compositions and methods of using the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| WO2004051268A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| US7771969B2 (en) | 2003-08-20 | 2010-08-10 | Celltech R&D Limited | Methods for obtaining antibodies |
| ES2385829T3 (es) | 2003-08-20 | 2012-08-01 | Ucb Pharma, S.A. | Métodos para obtener anticuerpos |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| WO2007031734A1 (en) | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A. | Comb polymers |
-
2006
- 2006-09-29 GB GBGB0619291.8A patent/GB0619291D0/en not_active Ceased
-
2007
- 2007-09-28 EP EP07804411A patent/EP2074143B1/de active Active
- 2007-09-28 DK DK07804411.2T patent/DK2074143T3/da active
- 2007-09-28 ES ES07804411T patent/ES2384807T3/es active Active
- 2007-09-28 AT AT07804411T patent/ATE554105T1/de active
- 2007-09-28 US US12/443,599 patent/US8507654B2/en not_active Expired - Fee Related
- 2007-09-28 WO PCT/GB2007/003706 patent/WO2008038024A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2384807T3 (es) | 2012-07-12 |
| WO2008038024A1 (en) | 2008-04-03 |
| US8507654B2 (en) | 2013-08-13 |
| US20100093977A1 (en) | 2010-04-15 |
| EP2074143A1 (de) | 2009-07-01 |
| EP2074143B1 (de) | 2012-04-18 |
| GB0619291D0 (en) | 2006-11-08 |
| DK2074143T3 (da) | 2012-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2074143T3 (da) | Ændrede antistoffer | |
| JO2778B1 (en) | Certain Compounds, Compositions and Methods | |
| NO20084878L (no) | Humanisert C-kit antistoff | |
| CY1113074T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| GB2468232A (en) | Antigen-bindng constructs | |
| JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
| CY1113199T1 (el) | Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης | |
| DE602007012559D1 (de) | H die schleimhaut | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| CY1114926T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
| BRPI0506679A (pt) | métodos de tratar osteoartrite com antagonistas de il-6 | |
| PH12013502230A1 (en) | Multispecific antibodies | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| BRPI0823506A8 (pt) | composições e métodos para a produção de isoprene | |
| EA200970580A1 (ru) | Таннат разагилина | |
| WO2009112245A9 (en) | Antibody against the csf-1 r | |
| WO2008027236A3 (en) | Multispecific antibodies | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| WO2009149200A3 (en) | Compositions and methods comprising variant microbial proteases | |
| BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof |